Coherus Oncology (CHRS) EBT Margin Growth (3y) (2016 - 2026)
Coherus Oncology (CHRS) EBT Margin Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -484.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 132.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 6,685.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -2,054.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8,006.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 9,980.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -9,922.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 31,363.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -5,319.00 |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -16,007.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16,007.00 |
| Mar 31, 2026 | -6,657.00 |
| Dec 31, 2025 | -23,376.00 |
| Sep 30, 2025 | -19,397.00 |
| Jun 30, 2025 | -35,413.00 |
| Mar 31, 2025 | -46,391.00 |
| Dec 31, 2024 | -53,378.00 |
| Sep 30, 2024 | -73,980.00 |
| Jun 30, 2024 | -49,863.00 |
| Mar 31, 2024 | -273,955.00 |
| Dec 31, 2023 | -9,677.00 |
| Sep 30, 2023 | -7,843.00 |
| Jun 30, 2023 | -11,747.00 |
| Mar 31, 2023 | -26,489.00 |
| Dec 31, 2022 | -16,312.00 |
| Sep 30, 2022 | -23,364.00 |
| Jun 30, 2022 | -11,168.00 |
| Mar 31, 2022 | -10,591.00 |
| Jun 30, 2020 | 486,146.00 |
| Mar 31, 2020 | 5.17 Mn |